Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 7/20 | 0.42 |
| ▸ | MMP1 | P03956 | 6/20 | 0.41 |
| ▸ | MMP2 | P08253 | 6/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258293 | 1.00 | L3MBTL1 (0.44) | L3MBTL1ALOX5MMP3MMP1MMP2 | |
| SCHEMBL6401370 | 0.90 | L3MBTL1 (0.40) | L3MBTL1ALOX5MMP3MMP1MMP2 | |
| SCHEMBL7257821 | 0.90 | L3MBTL1 (0.39) | L3MBTL1 | |
| SCHEMBL6403166 | 0.90 | L3MBTL1 (0.39) | L3MBTL1 | |
| SCHEMBL6407163 | 0.82 | CA1 (0.42) | L3MBTL1ALOX5MMP3MMP1MMP2 | |
| SCHEMBL6409442 | 0.82 | SLC7A5 (0.39) | L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6408723 | 0.79 | CA1 (0.41) | ALOX5MMP3MMP1MMP2PDE4A | |
| SCHEMBL6404802 | 0.78 | CASR (0.38) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL22327659 | 0.75 | L3MBTL1 (0.43) | L3MBTL1MMP3MMP2KMT2AMEN1 | |
| SCHEMBL5440422 | 0.74 | CTSK (0.46) | MMP3MMP1MMP2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | L3MBTL1 4162/4885ALOX5 1106/4885MMP3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.